Starting today, February 1, 2017 and running through midnight CST on June 30, 2017, you and a guest have the chance to win an all-expense paid trip* to Los Angeles, California, for a private dinner with critically acclaimed actor, Golden Globe winner and fellow Angelman parent Colin Farrell and world-renowned scientist Dr. Edwin Weeber! As
By Allyson Berent, DVM, DACVIM Recently published work from Dr. Edwin Weeber’s lab, funded by the FAST (Foundation for Angelman Syndrome Therapeutics), “demonstrates that ganaxolone ameliorates many of the behavioral abnormalities in the adult AS mouse, and tolerance did not occur to the therapeutic effects of the drug. The results support clinical studies to investigate
By Allyson Berent, DVM, DACVIM At the annual Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit in December, Jodi Cook, Ph.D., Chief Operating Officer for Agilis Biotherapeutics (Agilis), presented on gene therapy development for Angelman Syndrome (AS). Her presentation was very exciting for the community as we prepare to bring gene therapy treatment into human
“Of all the childhood genetic neurologic disorders of the brain, Angelman syndrome may be the single best candidate for developing a definitive treatment (aka a cure).”~Dr. Arthur Beaudet The Foundation for Angelman Syndrome Therapeutics (FAST) US and FAST AU are excited to announce joint funding to Dr. Beaudet to generate mouse lines expressing human UBE3A
Watch all the news and updates from the Science Summit 9-5pm Friday, December 2 (CST) and
the Education Summit on Saturday December 3, 9-4PM.
written by Allyson Berent, DVM DACVIM When we refer to gene therapy in Angelman Syndrome (AS), we are typically referring to a “viral delivery” or “virus vector” of the missing gene (UBE3A) or the missing protein (UBE3A protein) into the brain. AS is caused when the UBE3A gene is either missing or not functioning properly;
FAST (Foundation for Angelman Syndrome Therapeutics) has funded two research labs at the University of California, Davis (UC Davis) to further investigation into gene editing for Angelman Syndrome. One funded project continues the evaluation of Artificial Transcription Factors (ATFs or Zinc Fingers) for the treatment of Angelman Syndrome (AS) in Dr. David Segal’s laboratory (pictured
How FAST Is Changing The Landscape Of Angelman Research When you set out to cure an ‘incurable’ genetic disorder, you need three things: a comprehensive, well thought out plan; a dedicated and passionate community; and sufficient, often substantial funding. With a grant from the Marnier Lapostolle Foundation of $5.8 million, the Foundation for Angelman Syndrome
Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model
Read more about the exciting work that has earned the Segal Lab $1.1 Million for research.